MTIP
CRDF icon

Magee Thomson Investment Partners’s Cardiff Oncology CRDF Stock Holding History

Magee Thomson Investment Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9
Closed -$4K – 106
2015
Q4 		$4K Hold
9
– – ﹤0.01% 79
2015
Q3 		$4K Buy
9
+2
+29% +$1.05K ﹤0.01% 75
2015
Q2 		$5K Buy
+7
New +$4.96K ﹤0.01% 59

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Magee Thomson Investment Partners's CRDF Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Cardiff Oncology (CRDF) in Q1 2016, closing a stake of 9 shares — an estimated $4K sold.

Magee Thomson Investment Partners first reported a position in CRDF in Q2 2015 and held it in 3 quarters. The position peaked at $5K in Q2 2015. 58 funds tracked by Wall St. Rank hold CRDF as of Q1 2016.

  • Magee Thomson Investment Partners reported no remaining Cardiff Oncology position as of Q1 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 9 Cardiff Oncology shares in Q1 2016, an estimated $4K.
  • Magee Thomson Investment Partners first reported a position in Cardiff Oncology in Q2 2015 and held it in 3 quarters.
  • Magee Thomson Investment Partners's Cardiff Oncology position peaked at $5K in Q2 2015.
  • 58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.